Extrahepatic manifestations of chronic viral hepatitis C

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Chronic viral diseases of the liver are frequently characterized by clinical signs of intrahepatic complications. Infection caused by the hepatitis C virus should be considered as a systemic disorder associated with the frequent development of various extrahepatic complications, such as cryoglobulinemia, glomerulopathy, lymphoproliferative diseases, seronegative arthritis, type 2 diabetes mellitus, lichen planus, and late cutaneous porphyria. Often, extrahepatic complications become the main features of the clinical disease picture, forcing patients to seek medical help from various specialists and delaying diagnosis. In some cases, the treatment of extrahepatic manifestations becomes an independent, complex task, surpassing the actual treatment of chronic hepatitis C. The relationship between hepatic and extrahepatic complications of viral hepatitis C is not linear; rather, extrahepatic manifestations often outstrip the development of liver damage. The effects of hepatitis C virus on the organs and systems of the body are caused by the direct action of the virus, pathogenetically induced by the development of steatosis/steatohepatitis, and by the disruption of system regulation of hepatokines and cytokines. Treatment of chronic hepatitis C virus infection should be comprehensive and should include antiviral therapy, treatment of metabolic-associated fatty liver disease and treatment of hepatic-related disorders. Antiviral therapy with preparations of direct antiviral action allows the prevention of not only liver complications but also of many extrahepatic complications of hepatitis C virus. Comorbid states significantly increase the natural progression of chronic hepatitis C infection and vice versa: the hepatitis C virus increases the clinical manifestations of co-pathology. In the age of direct antiviral drugs, it is possible to eliminate the hepatitis C virus, but in some cases, elimination alone does not arrest the progression of liver disease.

About the authors

Evgeniy V. Kryukov

Military Medical Academy of S.M. Kirov

Email: evgeniy.md@mail.ru
ORCID iD: 0000-0002-8396-1936
SPIN-code: 3900-3441
Scopus Author ID: 57208311867
ResearcherId: AAO-9491-2020

Doctor of Medical Sciences, Professor

Russian Federation, Saint Petersburg

Dmitry V. Cherkashin

Military Medical Academy of S.M. Kirov

Email: cherkashin_dmitr@mail.ru
ORCID iD: 0000-0003-1363-6860
SPIN-code: 2781-9507

Doctor of Medical Sciences, Professor

Russian Federation, Saint Petersburg

Vladimir V. Saluhov

Military Medical Academy of S.M. Kirov

Email: vlasaluk@yandex.ru
ORCID iD: 0000-0003-1851-0941
SPIN-code: 4531-6011

Doctor of Medical Sciences, Professor

Russian Federation, Saint Petersburg

Konstantin V. Matjushenko

Military Medical Academy of S.M. Kirov

Email: kvmat@mail.ru
ORCID iD: 0000-0002-7399-3694
SPIN-code: 8656-9671

Candidate of Medical Sciences

Russian Federation, Saint Petersburg

Aleksey D. Sobolev

Military Medical Academy of S.M. Kirov

Author for correspondence.
Email: sobolevvmeda@rambler.ru
ORCID iD: 0000-0003-1908-7954
SPIN-code: 3831-6584

Teacher

Russian Federation, Saint Petersburg

Nikolaj N. Shcherbina

Military Medical Academy of S.M. Kirov

Email: n.shcherbina@list.ru
ORCID iD: 0000-0003-4550-1514

Candidate of Medical Sciences

Russian Federation, Saint Petersburg

References

  1. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342. doi: 10.1002/hep.26141
  2. Cacoub P, Rosenthal E. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus. 2015;24(4–5):469–482. doi: 10.1177/0961203314556140
  3. Chernov VS, Kozlov KV, Paltusov EP, Kuznetsov PL. Chronic hepatitis c: a review of the current literature. Ural Medical Journal. 2019. № 9. С. 85–93. (In Russ.). doi: 10.25694/URMJ.2019.09.16
  4. Zhdanov KV, Yaremenko MV, Kozlov KV, et al. Non-invasive diagnosis of fibrosis in patients with CHC and obesity. Journal Infectology. 2020;12(1):40–47. (In Russ.). doi: 10.22625/2072-6732-2020-12-1-40-47
  5. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42(4):962–973. doi: 10.1002/hep.20819
  6. Kalinina OV. Hepatitis C virus: variability mechanisms, classification, evolution. Problems of Virology. 2015;60(5):5–10. (In Russ.).
  7. Galossi A, Guarisco R, Bellis L, et al. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis. 2007;16(1):65.
  8. Kryukov EV, Pop VP, Rukavitsyn OA. Hematological disorders in patients with chronic hepatitis c and approaches to the treatment. Infectious Diseases: News, Opinions, Training. 2018;(3):95–101. (In Russ.). doi: 10.24411/2305-3496-2018-13014
  9. Kryukov EV, Pop VP, Rukavitsyn OA. Interactions between hepatitis viruses and lymphoid tissue; modern possibilities of treatment of virus-associated lymphomas. Infectious Diseases: News, Opinions, Training. 2017;(6):53–61. (In Russ.). doi: 10.24411/2305-3496-2017-00005
  10. Jukić LV, Kralj D. Extrahepatic Manifestations of Hepatitis C Virus Infection. In: Smolic M, Vcev A, Wu GY, editors. Update on Hepatitis C. London: IntechOpen; 2017. doi: 10.5772/intechopen.70728
  11. Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: A constellation of organ-and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol. 2015;7(3):327–343. doi: 10.4254/wjh.v7.i3.327
  12. Cacoub P, Desbois AC, Isnard-Bagnis C, et al. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol. 2016;65(1):S82–S94. doi: 10.1016/j.jhep.2016.06.011
  13. Kuna L, Jakab J, Smolic R, et al. HCV Extrahepatic Manifestations. J Clin Transl Hepatol. 2019;7(2):172–182. doi: 10.14218/JCTH.2018.00049
  14. Maslennikov R, Ivashkin V, Efremova I, Shirokova E. Immune disorders and rheumatologic manifestations of viral hepatitis. World J Gastroenterol. 2021;27(18):2073–2089. doi: 10.3748/wjg.v27.i18.2073
  15. Adinolfi LE, Rinaldi L, Guerrera B, et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016;17(6):803. doi: 10.3390/ijms17060803
  16. Fouad Y, Waked I, Bollipo S, et al. What’s in a name? Renaming NAFLD to MAFLD. Liver International. 2020;40(6):1254–1261. doi: 10.1111/liv.14478
  17. Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014. doi: 10.1053/j.gastro.2019.11.312
  18. Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263–8276. doi: 10.3748/wjg.v23.i47.8263
  19. Zhdanov KV, Karyakin SS, Kozlov KV, et al. Chronic hepatitis С and non-alcoholic fatty liver disease. Main aspects of pathogenesis. Bulletin of the Russian Military Medical Academy. 2018;20(1): 216–2211. (In Russ.). doi: 10.17816/brmma12326
  20. Wang F, So K-F, Xiao J, Wang H. Organ-organ communication: The liver’s perspective. Theranostics. 2021;11(7):3317–3330. doi: 10.7150/thno.55795
  21. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327: 1490–1495. doi: 10.1056/NEJM199211193272104
  22. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C Virus Infection in Patients with Essential Mixed Cryoglobulinemia. Ann Intern Med. 1992;117(7):573–577. doi: 10.7326/0003-4819-117-7-573
  23. Ferri C, Ramos-Casals M, Zignego AL, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15(12):1145–1160. doi: 10.1016/j.autrev.2016.09.006
  24. Damoiseaux J. The diagnosis and classification of the cryoglobulinemic syndrome. Autoimmun Rev. 2014;13(4–5):359–362. doi: 10.1016/j.autrev.2014.01.027
  25. Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017;129(3):289–298. doi: 10.1182/blood-2016-09-719773
  26. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369:1035–1045. doi: 10.1056/NEJMra1208642
  27. Perez S, Kaspi A, Domovitz T, et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genetics. 2019;15(6):e1008181. doi: 10.1371/journal.pgen.1008181
  28. Adinolfi LE, Zampino R, Restivo L, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20(13):3410. doi: 10.3748/wjg.v20.i13.3410
  29. Morozova TS. Kliniko-patogeneticheskie podkhody k prognozirovaniyu kardiovaskulyarnykh oslozhnenii u patsientov s khronicheskimi virusnymi zabolevaniyami pecheni [dissertation abstract]. Yekaterinburg, 2021. 50 p. (In Russ.).
  30. Alavi M, Law MG, Valerio H, et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol. 2019;71(2):281–288. doi: 10.1016/j.jhep.2019.04.014
  31. Shengir M, Elgara M, Sebastiani G. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. World J Gastroenterol. 2021;27(17):1959–1972. doi: 10.3748/wjg.v27.i17.1959
  32. Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nature Reviews Disease Primers. 2017;3:17006. doi: 10.1038/nrdp.2017.6
  33. Lazebnik LB, Golovanova EV, Turkina SV, et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4–52. (In Russ.). doi: 10.31146/1682-8658-ecg-185-1-4-52
  34. Frosi A. Extrahepatic Manifestations of Hepatitis C Infection. In: Rodrigo L, Martins I, Guo X, Qi X, editors. Advances in Hepatology. London: IntechOpen, 2021. doi: 10.5772/intechopen.95995
  35. Zhdanov KV, Kozlov KV, Sukachev VS, Zhabrov SS. Real-world clinical practice and future prospects of interferon-free therapy in patients with chronic hepatitis C (genotype 1). Infectious Diseases. 2018;16(2):98–103. (In Russ.). doi: 10.20953/1729-9225-2018-2-98-10

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Extrahepatic manifestations of chronic viral hepatitis B and chronic viral hepatitis C

Download (361KB)
3. Fig. 2. Model of synergistic epidemic on the example of viral hepatitis C

Download (328KB)
4. Fig. 3. Scheme of the consequences of disorders of cytokine and hepatokine regulation: FAS —fatty acid sequestrants; 5-HT — 5-hydroxytryptamine; IgA — immunoglobulin A; ARF — acute renal failure; CRF — chronic kidney disease; AMI — acute myocardial infarction; BP — blood pressure

Download (531KB)
5. Fig. 4. Association of chronic HCV (hepatitis C virus) infection with the development of atherosclerosis

Download (614KB)
6. Fig. 5. Impact of sustained virologic response on hepatic and extrahepatic (cardiometabolic) manifestations associated with HCV infection

Download (543KB)
7. Fig. 6. Methods of therapy for metabolic-associated fatty liver disease

Download (286KB)
8. Fig. 7. Modern paradigm of viral hepatitis treatment–multidisciplinary approach

Download (518KB)

Copyright (c) 2022 Kryukov E.V., Cherkashin D.V., Saluhov V.V., Matjushenko K.V., Sobolev A.D., Shcherbina N.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies